Clinical trial
Immediate Versus Deferred Androgen Deprivation Therapy,Goserelin for Recurrent…
NCT00439751 · Ontario Clinical Oncology Group (OCOG), Other · Completed
Key facts
| NCT number | NCT00439751 |
|---|---|
| Title | Immediate Versus Deferred Androgen Deprivation Therapy,Goserelin for Recurrent Prostate Cancer After Radical Radiotherapy |
| Official title | A Randomized Comparison of Immediate Versus Deferred Androgen Deprivation Therapy Using Goserelin for Recurrent Prostate Cancer After Radical Radiotherapy. |
| Acronym | ELAAT |
| Lead sponsor | Ontario Clinical Oncology Group (OCOG), Other |
| Collaborators | AstraZeneca Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug |
| Interventions | Goserelin Acetate |
| Enrollment | 79 |
| Start date | Apr 1, 2007 |
| Primary completion | Dec 1, 2015 |
| Completion | Jun 1, 2016 |
| First posted | Feb 26, 2007 |
| Last update posted | Jul 12, 2016 |
| Countries | Canada |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: